Peripheral Blood T Cell Ratio Predicts Checkpoint Inhibitor Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly immunotherapies targeting the PD-1/PD-L1 axis, face variability in patient response due to differences in tumor type, mutation burden, and pre-existing antitumor immunity, necessitating a method to identify patients more likely to benefit from anti-PD-1 or anti-PD-L1 antibody therapies.
Innovation Solution
Determining the ratio of circulating central memory T cells to effector memory T cells in patients, which correlates with the inflammatory milieu at the tumor site, to predict the likelihood of response to checkpoint inhibitors and guide treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy targeting PD-1/PD-L1 axis is administered to all patients, then some patients may benefit from treatment, but response variability is high and many patients do not respond
Solution Approach 1:
The patent applies preliminary action by measuring the TCM:Teff ratio in peripheral blood before administering checkpoint inhibitors to predict which patients are likely to respond. This pre-treatment biomarker assessment allows clinicians to identify suitable candidates in advance, avoiding ineffective treatments and improving overall response rates by selecting patients with inflammatory tumor microenvironments who are more likely to benefit from immunotherapy
2Measurement precision
If tumor biopsy is performed to assess inflammatory milieu, then accurate prediction of treatment response is possible, but the procedure is invasive and complex
Solution Approach 1:
The patent uses peripheral blood T cell ratios as an intermediary biomarker that reflects the inflammatory status of the tumor microenvironment without requiring direct tumor sampling. The TCM:Teff ratio in circulating blood serves as a non-invasive surrogate marker that correlates with the inflammatory milieu at the tumor site, enabling accurate prediction of checkpoint inhibitor response through simple blood tests rather than complex biopsy procedures
Solution Approach 2:
The patent replaces the mechanical/invasive procedure of tumor biopsy with a minimally invasive blood draw to assess the same biological parameter (inflammatory status). By measuring T cell ratios in peripheral blood instead of directly sampling tumor tissue, the method substitutes a complex invasive diagnostic system with a simpler, safer, and more patient-friendly approach while maintaining predictive accuracy
3Productivity
If checkpoint inhibitors are administered without patient selection, then treatment coverage is maximized, but resource utilization is inefficient and treatment duration may be extended without benefit
Solution Approach 1:
The patent implements preliminary patient selection using the TCM:Teff ratio biomarker before initiating checkpoint inhibitor therapy. By assessing this peripheral blood parameter in advance, clinicians can identify patients with inflammatory tumor microenvironments who are likely to respond, thereby maximizing productive treatment coverage while avoiding unnecessary treatment time and resource consumption for patients who would not benefit from the therapy
Data Source
AI summary
The present disclosure relates to the finding that the ratio of circulating (i.e., peripheral blood) central memory T cells to circulating effector T cells in a cancer patient can predict whether a tumor has an inflammatory milieu or not. In addition, since having an inflammatory milieu (“hot tumor”) is a positive factor for responding to checkpoint inhibitors, e.g., PD-1 antagonists, this assay on peripheral blood can also be used to predict a response to a checkpoint inhibitor, e.g., an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or an antibody or an antigen binding portion thereof that binds specifically to PD-1 ligand 1 (PD-L1) and inhibits PD-L1 activity.